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-TuRC gives microtubules pause for thought
A 
protein complex 
better known for its 
role in microtubule 
nucleation at the centrosome 
is also a stabilizing factor 
that controls cytoskeletal 
-Tubulin and its part-
ners in the -tubulin ring 
complex (-TuRC) initiate the 
growth of new microtubules. 
This is particularly important during mitosis—cells missing -TuRC 
subunits either fail to divide or go through the process slowly. Little is 
known about the complex’s function in interphase, however.
Bouissou et al. depleted several -TuRC components 
(including -tubulin itself) in Drosophila cells and found that 
microtubule organization was unaffected. But live microscopy 
revealed that the microtubules in these cells were more dynamic 
and more likely to switch from growing to shrinking, whereas 
microtubules from control cells often remained paused. The 
researchers saw -TuRC dotting the length of microtubules, 
and determined that these spots corresponded to sites where 
dynamic microtubules would either pause or begin to regrow. 
Microtubules tended not to depolymerize past the points of 
-TuRC, suggesting that the complex acts as a stabilizing factor, 
perhaps by counteracting the binding of other microtubule-
associated proteins that promote disassembly.
Because  Drosophila cell microtubules are arranged 
somewhat differently to those in most animal cells, the group 
now wants to see whether -TuRC has a similar function in other 
cell types. Senior author Brigitte Raynaud-Messina also plans to 
investigate whether the complex regulates specialized subsets of 
microtubules that particularly need stabilizing.
Raf-1 sheds then spreads its inhibitions
T
he regulatory do-
main of the kinase 
Raf-1 switches from 
inhibiting its own protein’s 
activity to blocking a differ-
ent kinase in a separate sig-
type of signaling cross talk.
two kinases, activated re-
spectively by the small GTPases Ras and Rho. Before their 
activation, both kinases keep themselves quiet through intra-
molecular interactions between their inhibitory regions and 
catalytic domains. Activated Raf-1 also keeps Rok- in check 
to promote cell migration, survival, and tumorigenesis—the 
inhibition of Rok- by Raf-1 is essential for the development 
and maintenance of Ras-induced epidermal tumors. But how 
this cross talk occurs is unclear.
Niault et al. found that when both kinases are activated by 
their GTPases, the regulatory domain of Raf-1 binds directly to 
the Rok- kinase region to attenuate its activity. Cells lacking 
Raf-1  are abnormally shaped, migrate more slowly, and are 
more sensitive to cell death due to Rok- overactivation, but the 
reintroduction of the Raf-1 regulatory domain alone reversed 
these phenotypes by blocking Rok- function.
The inhibition of one kinase by another through direct 
binding is a new kind of regulation, says senior author Manuela 
Baccarini—cross talk between kinases and different signaling 
pathways is usually achieved through phosphorylation. Given the 
interaction’s importance in cancer progression, Baccarini now 
wants to develop molecules that block the inhibitory association, 
and test these in animal tumor models.
Cells lacking Raf-1 contract due to 
Rok- overactivation (left). Raf-1’s 
regulatory domain inhibits Rok- 
and restores normal cell shape (right).
Chemosensitivity depends on the dependency
T
wo different anti-apoptotic proteins support cancer cell 
survival via an identical mechanism, yet differ in their 
Cancer cells often become dependent on one or more anti-
apoptotic proteins to avoid death while continuing to proliferate. 
BCL-2, for example, is overexpressed in many cancers and mops 
up pro-apoptotic proteins to prevent them from permeabilizing 
mitochondria and initiating cell death. Other tumors are reliant 
on a related protein called MCL-1, but less is known about this 
member of the BCL-2 family. Brunelle et al. created leukemic 
mice overexpressing MCL-1 and compared them to similar mice 
that produced excess BCL-2.
The leukemias suffered by these two types of mice were iden-
tical, yet a technique called BH3 profi  ling was able to distinguish 
between cells derived from the different animals by demonstrating 
a dependency on one or other of the two anti-apoptotic proteins. 
Immunoprecipitation experiments revealed that MCL-1 and 
BCL-2 both work by sequestering the same two pro-apoptotic targets. 
Surprisingly then, leukemia cells reliant on MCL-1 were much more 
sensitive to a range of chemotherapeutic drugs than their BCL-2– 
dependent counterparts were. Brunelle et al. found that the different 
cytotoxic drugs all caused a rapid decrease in MCL-1 protein levels 
via proteosome-mediated degradation, allowing cell death to proceed 
quickly. BCL-2 protein is more stable however, so additional time 
and more drug is needed to kill BCL-2–dependent cancer cells.
Thus, the block in apoptosis selected during oncogenesis 
is not necessarily complete, and can have a major infl  uence on 
the cancer’s chemosensitivity. Senior author Anthony Letai now 
plans to use BH3 profi  ling on human tumors, to determine which 
anti-apoptotic protein a patient’s cancer is dependent on and to 
correlate this with the tumor’s response to chemotherapy.
-TuRC (green) acts as a stabilizing 
factor along the length of micro-
tubules (red).
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